POCare Therapies

Bringing Promising Therapeutics to Market

Most research and biotechnology entities are good at science but need help with their development strategy and the scale up process to treat patients.

We identify promising therapies and bring their development into our POCare Platform to overcome these challenges.

The result: a pipeline of advanced therapies that are expertly and efficiently brought to market for point of care production and use.

Partnering for the Benefit of Patients

Our POCare Platform seeks to accelerate the development of life-changing therapies to potentially reduce costs to the healthcare system.

Partners benefit from Orgenesis’ extensive know-how in CGT process development and validation, and we benefit from long-term economic opportunities through processing licenses and royalties at the POCare Network level.

Therapies Pipeline

  • Immuno-Oncology
  • Viral Diseases
  • Metabolic & Autoimmune Diseases
  • Vascular & Musculoskeletal Diseases
  • Kidney Disease
  • Program
  • Indications
  • Preclinical
  • IND Enabling Studies
  • Clinical Trials
  • Clinical Use
Immuno-Oncology
B-ALL, Lymphoma
An advanced monomeric anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) therapy to treat relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) patients.
Lung Cancer; Melanoma
An anti-cancer cellular vaccine that utilizes patient antigen presenting cells (APCs) pulsed with relevant cancer cells to target the entire repertoire of tumour cell antigens and elicit immune response against hard to treat cancers.
Solid Tumors; Pancreatic Cancer
An adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) as a personalized cancer treatment platform via infusion of autologous T lymphocytes expanded from tumors. A complementary cellular biomanufacturing platform is being developed based on a novel metabolic sensor to optimize the harvest time and increase therapeutic potential of the T-cells.
B-ALL
A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.
Multiple Myeloma, Ovarian Cancer
A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.
Viral Diseases
HPV: Genital Warts; Anal Dysplasia
Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.
Covid-19 Related ARDS
Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.
Covid-19 Vaccine
A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.
Metabolic & Autoimmune Diseases
Chronic Pancreatitis
Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.
Liver, Kidney and Dermatological Diseases
A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.
Psoriasis; Wound Healing
A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.
Vascular & Musculoskeletal Diseases
Osteoarthritis
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.
Erectile Dysfunction, CLI
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.
Musculoskeletal Diseases
Synthetic exosomes/extracellular vesicles that have demonstrated the ability to fuse with cell membranes and deliver intracellular cargo in a similar manner to natural exosomes. Bioxome can carry selected therapeutic cargo inside target cells, to induce a variety of therapeutic applications. Currently developed to treat Kidney and Liver Disorders.
Kidney Disease
Acute and Chronic Kidney Diseases
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.
Chronic Kidney Diseases
A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.